AstraZeneca Raises Forecast, Expands US R&D with $2B

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year as the London-listed company doubled down on plans for US expansion, announcing $2 billion in new spending on research and development https://x.com/Reuters/status/1856468264571863086